, 2011, Talecris offered retention amounts totaling approximately $9.8 million to employees of which $2.9 million was paid during 2010 and $3.5 million was paid during the first quarter of 2011. The remaining amounts of approximately $3.4 million will be paid two months after the Closing Date, or in the event of termination of the definitive merger agreement, the earlier of four months after the termination of the definitive merger agreement or June 3, 2011. Talecris incurred retention expense, including fringe benefits, of $2.7 million during the three months ended March 31, 2011. The remaining retention amounts of approximately $1.8 million, including fringe benefits, will be recognized during the second quarter of 2011.
Share-Based Compensation AwardsThe company has long-term incentive plans, which provide for the grant of awards in the form of incentive stock options, non-qualified stock options, share appreciation rights, restricted stock, restricted stock units (RSUs), unrestricted shares of common stock, deferred share units, and performance share units (PSUs), to eligible employees, directors, and consultants.
The following table summarizes the company's share-based compensation expense:Three Months EndedMarch 31,20112010SG&A$
5,680R&D112538Total operating expenses1,6826,218Cost of goods sold5301,009Total expense$
7,227The decrease in share-based compensation expense period over period was driven by the final vesting of awards under the 2005 Stock Option and Incentive Plan on April 1, 2010 and the majority of the awards under the company's 2006 Restricted Stock Plan on March 31, 2010.
EXHIBIT B: NON-GAAP FINANCIAL MEASURESDescription of Adjustments and Reconciliations of U.S. GAAP to Non-GAAP Financial Measures
Merger-related Items and Interest on PCA JudgmentTalecris believes a meaningful comparison of its results for the periods presented is e
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related biology technology :1
|SOURCE Talecris Biotherapeutics Holdings Corp.|
Copyright©2010 PR Newswire.
All rights reserved
. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement2
. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.3
. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics 4
. Siemens/Talecris Win Best Partnership in the Outsourcing Excellence Awards5
. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results6
. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference7
. Talecris Added to NASDAQ Biotechnology Index8
. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference9
. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations10
. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management11
. Talecris Biotherapeutics Announces Premerger HSR Filing